Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prevention of Asthma Relapse After Discharge From Emergency (PARADE)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00326053
First received: May 12, 2006
Last updated: January 21, 2011
Last verified: January 2011

May 12, 2006
January 21, 2011
May 2006
Not Provided
Time to first asthma relapse
Same as current
Complete list of historical versions of study NCT00326053 on ClinicalTrials.gov Archive Site
  • Mean use of reliever medication
  • Asthma Control Questionnaire (ACQ) score
  • Complete AE and SAE collection
Same as current
Not Provided
Not Provided
 
Prevention of Asthma Relapse After Discharge From Emergency
A Comparison of Budesonide/Formoterol Turbuhaler® 160/4.5 µg 2 Inhalations BID Plus as Needed to Budesonide Turbuhaler® 320 µg 2 Inhalations BID Plus Terbutaline Turbuhaler® 0.4 mg as Needed for the Prevention of Asthma Relapse

The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Asthma
Drug: Budesonide/formoterol
Other Name: Symbicort
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
600
May 2007
Not Provided

Inclusion Criteria:

  • 18 - 65 years of age
  • Presenting at a study emergency department with an asthma exacerbation

Exclusion Criteria:

  • Admission to hospital
  • Patients receiving more than 2000 µg/day of beclomethasone equivalent inhaled corticosteroids (1000 µg/day fluticasone or 1600 µg/day budesonide)
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00326053
D5890L00017, PARADE
Not Provided
Not Provided
AstraZeneca
Not Provided
Study Director: Gloria Jordana, MD AstraZeneca
Principal Investigator: Brian Rowe, MD University of Alberta
AstraZeneca
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP